<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000756463"><TermName>amatuximab</TermName><TermPronunciation>(A-muh-TUK-sih-mab)</TermPronunciation><TermDefinition><DefinitionText>A substance being studied in the treatment of mesothelioma. Amatuximab binds to a protein called mesothelin, which is found on some cancer cells. Amatuximab may help the immune system kill cancer cells. It is a type of monoclonal antibody. Also called anti-mesothelin monoclonal antibody MORAb-009 and MORAb-009.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000760882" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;amatuximab&quot;" language="en" id="_3"/><MediaLink ref="CDR0000760881" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;amatuximab&quot;" language="es" id="_4"/><SpanishTermName>amatuximab</SpanishTermName><SpanishTermDefinition><DefinitionText>Sustancia en estudio para el tratamiento del mesotelioma. El amatuximab se une a una proteína llamada mesotelina, que se encuentra en algunas células cancerosas. El amatuximab podría ayudar al sistema inmunitario a destruir células cancerosas. Es un tipo de anticuerpo monoclonal. También se llama anticuerpo monoclonal MORAb-009 anti mesotelina y MORAb-009.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2014-03-10</DateFirstPublished><DateLastModified>2014-03-10</DateLastModified></GlossaryTerm>
